drugset / Trial / NCT02466009
Regorafenib in Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
Timeline
- Start
- 2015-03
- Primary completion
- 2019-07
- Completion
- 2022-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | Oral |